Microarray based gene expression: a novel approach for identification and development of potential drug and effective vaccine against visceral Leishmaniasis
Keywords:
Visceral Leishmaniasis, Microarray, Stage-specific, Gene expression profiling, Gene discovery, Novel vaccine/drug targetsAbstract
Visceral Leishmaniasis (VL) is the well-recognized infectious disease among the complex of Leishmaniasis (cutaneous, mucocutaneous, visceral) in tropical and subtropical countries. Treatments for VL are unsatisfactory till date and alarming rise of drug resistance is a serious problem. Vaccines to control VL have shown some promise, but none are in current clinical use. Therefore, urgent needs for new and effective anti-leishmanials are prerequisite. To identify the potential factors, DNA microarray an advance, high throughput technology, has open the possibility of discovering new genes that can contribute to vaccine initiatives or serve as potential drug targets. It has been successfully applied to many of the protozoan parasites and identified some new genes as targets. Target discovery is the key step in the biomarker and drug discovery pipeline to diagnose. After the completion of genome sequencing of Leishmania major and L. infantum, advancement in microarray technologies provide new approaches to study the pattern of gene expression profile during differentiation and development of parasite. It has the potential to improve our understanding of pathogenicity, mechanism of drug resistance and virulence factors by identifying up/down regulated gene and characterizing the respective gene expression. Keeping these backgrounds in mind, we reviewed the data obtained from genome-wide wide expression profiling in Leishmania that focuses on applications of microarray in novel vaccine/drug targets discovery for VL and discuss the potential avenues for their future investigation. Ultimately this will be able to translate the findings into the development of novel therapeutic approaches and targets for VL.
References
Herwaldt BL. Leishmaniasis. Lancet 1999; 354:
-1199.
Sundar S. Drug resistance in Indian visceral
leishmaniasis. Trop Med Int Health 2001; 6: 849-
Rees PH, Kager PA, Wellde BT, Hockmeyer WT.
The response of Kenyan kala-azar to treatment
with sodium stibogluconate. Am J Trop Med Hyg
; 33: 357-361.
Salotra P, Duncan RC, Singh R, Subba Raju BV,
Sreenivas G, Nakhasi HL. Upregulation of surface
proteins in Leishmania donovani isolated from
patients of post kala-azar dermal leishmaniasis.
Microbes Infect 2006; 8: 637-344.
Desjeux P. Leishmaniasis: current situation and
new perspectives. Comp Immunol Microbiol Infect
Dis 2004; 27: 305-318.
Thakur BB. Breakthrough in the management of
visceral leishmaniasis. J Assoc Physicians India
; 51: 649-651.
Bora D. Epidemiology of visceral leishmaniasis in
India. Natl Med J India 1999; 12: 62-68.
Zijlstra EE, el-Hassan AM, Ismael A. Endemic
kala-azar in eastern Sudan: post-kala-azar dermal
leishmaniasis. Am J Trop Med Hyg 1995; 52: 299-
Sacks DL, Perkins PV. Development of infective
stage Leishmania promastigotes within
phlebotomine sand flies. Am J Trop Med Hyg
; 34: 456-459.
Handman E. Cell biology of Leishmania. Adv
Parasitol 1999; 44: 1-39.
Bellatin JA, Murray AS, Zhao M, McMaster WR.
Leishmania mexicana: identification of genes that
are preferentially expressed in amastigotes. Exp
Parasitol 2002; 100: 44-53.
Duncan R, Alvarez R, Jaffe CL. Early response
gene expression during differentiation of cultured
Leishmania donovani. Parasitol Res 2001; 87: 897-
Bozdech Z, Zhu J, Joachimiak MP, Cohen FE,
Pulliam B, DeRisi JL. Expression profiling of the
schizont and trophozoite stages of Plasmodium
falciparum with a long-oligonucleotide microarray.
Genome Biol 2003; 4: R9.
Cleary MD, Singh U, Blader IJ, Brewer JL,
Boothroyd JC. Toxoplasma gondii asexual
development: identification of developmentally
regulated genes and distinct patterns of gene
expression. Eukaryot Cell 2002; 1: 329-340.
Hayward RE, Derisi JL, Alfadhli S, Kaslow DC,
Brown PO, Rathod PK. Shotgun DNA microarrays
and stage-specific gene expression in Plasmodium
falciparum malaria. Mol Microbiol 2000; 35: 6-14.
Clarke PA, te Poele R, Workman P. Gene
expression microarray technologies in the
development of new therapeutic agents. Eur J
Cancer 2004; 40: 2560-2591.
Pritchard JF, Jurima-Romet M, Reimer ML,
Mortimer E, Rolfe B, Cayen MN. Making better
drugs: Decision gates in non-clinical drug
development. Nat Rev Drug Discov 2003; 2: 542-
Wang S, Cheng Q. (2006) Microarray analysis in
drug discovery and clinical applications. Methods
Mol Biol 316: 49-65.
Quijada L, Soto M, Requena JM. Genomic DNA
macroarrays as a tool for analysis of gene
expression in Leishmania. Exp Parasitol 2005;
: 64-70.
Chaussabel D, Semnani RT, McDowell MA, Sacks
D, Sher A, Nutman TB. Unique gene expression
profiles of human macrophages and dendritic cells
to phylogenetically distinct parasites. Blood 2003;
: 672-681.
Duncan R. DNA microarray analysis of protozoan
parasite gene expression: outcomes correlate with
mechanisms of regulation. Trends Parasitol 2004;
: 211-215.
Hu Y, Uttamchandani M, Yao SQ. Microarray: a
versatile platform for high-throughput functional
proteomics. Comb Chem High Throughput Screen
; 9: 203-212.
Wang S, Sim TB, Kim YS, Chang YT. Tools for
target identification and validation. Curr Opin
Chem Biol 2004; 8: 371-377.
Saxena A, Worthey EA, Yan S, Leland A, Stuart
KD, Myler PJ. Evaluation of differential gene
expression in Leishmania major Friedlin procyclics
and metacyclics using DNA microarray analysis.
Mol Biochem Parasitol 2003; 129: 103-114.
Wu X, Dewey TG. From microarray to biological
networks: Analysis of gene expression profiles.
Methods Mol Biol 2006; 316: 35-48.
Marasca R, Maffei R, Zucchini P. Gene expression
profiling of acute promyelocytic leukaemia
identifies two subtypes mainly associated with flt3
mutational status. Leukemia 2006; 20: 103-114.
Bullinger L, Dohner K, Bair E. Use of geneexpression profiling to identify prognostic
subclasses in adult acute myeloid leukemia. N Engl
J Med 2004; 350: 1605-1616.
Valk PJ, Verhaak RG, Beijen MA. Prognostically
useful gene-expression profiles in acute myeloid
leukemia. N Engl J Med 2004; 350: 1617-1628.
Debnath A, Das P, Sajid M, McKerrow JH.
Identification of genomic responses to collagen
binding by trophozoites of Entamoeba histolytica.
J Infect Dis 2004; 190: 448-457.
MacFarlane R, Bhattacharya D, Singh U. Genomic
DNA microarrays for Entamoeba histolytica:
applications for use in expression profiling and
strain genotyping. Exp Parasitol 2005; 110: 196-
Guimond C, Trudel N, Brochu C. Modulation of
gene expression in Leishmania drug resistant
mutants as determined by targeted DNA
microarrays. Nucleic Acids Res 2003; 31: 5886-
Almeida R, Gilmartin BJ, McCann SH. Expression
profiling of the Leishmania life cycle: cDNA
arrays identify developmentally regulated genes
present but not annotated in the genome. Mol
Biochem Parasitol 2004; 136: 87-100.
Diehl S, Diehl F, El-Sayed NM, Clayton C,
Hoheisel JD. Analysis of stage-specific gene
expression in the bloodstream and the procyclic
form of Trypanosoma brucei using a genomic
DNA-microarray. Mol Biochem Parasitol 2002;
: 115-123.
Holzer TR, McMaster WR, Forney JD. Expression
profiling by whole-genome interspecies microarray
hybridization reveals differential gene expression
in procyclic promastigotes, lesion-derived
amastigotes, and axenic amastigotes in Leishmania
mexicana. Mol Biochem Parasitol 2006; 146: 198-
Rochette A, Raymond F, Ubeda JM. Genome-wide
gene expression profiling analysis of Leishmania
major and Leishmania infantum developmental
stages reveals substantial differences between the
two species. BMC Genomics 2008; 9: 255.
Srividya G, Duncan R, Sharma P, Raju BV,
Nakhasi HL, Salotra P. Transcriptome analysis
during the process of in vitro differentiation of
Leishmania donovani using genomic microarrays.
Parasitology 2007; 134: 1527-1539.
Saxena A, Lahav T, Holland N. Analysis of the
Leishmania donovani transcriptome reveals an
ordered progression of transient and permanent
changes in gene expression during differentiation.
Mol Biochem Parasitol 2007; 152: 53-65.
McNicoll F, Drummelsmith J, Muller M. A
combined proteomic and transcriptomic approach
to the study of stage differentiation in Leishmania
infantum. Proteomics 2006; 6: 3567-3581.
Alcolea PJ, Alonso A, Sanchez-Gorostiaga A.
Genome-wide analysis reveals increased levels of
transcripts related with infectivity in peanut lectin
non-agglutinated promastigotes of Leishmania
infantum. Genomics 2009; 93: 551-564.
Ettinger NA, Wilson ME. Macrophage and T-Cell
Gene Expression in a Model of Early Infection
with the Protozoan Leishmania chagasi. PLoS
Negl Trop Dis 2008; 2: e252.
Rodriguez A, Martinez N, Camacho FI. Variability
in the degree of expression of phosphorylated
IkappaBalpha in chronic lymphocytic leukemia
cases with nodal involvement. Clin Cancer Res
; 10: 6796-6806.
El Fadili K, Imbeault M, Messier N. Modulation of
gene expression in human macrophages treated
with the anti-leishmania pentavalent antimonial
drug sodium stibogluconate. Antimicrob Agents
Chemother 2008; 52: 526-533.
Gregory DJ, Sladek R, Olivier M, Matlashewski G.
Comparison of the effects of Leishmania major or
Leishmania donovani infection on macrophage
gene expression. Infect Immun 2008; 76: 1186-
Buates S, Matlashewski G. General suppression of
macrophage gene expression during Leishmania
donovani infection. J Immunol 2001; 166: 3416-
Rochette A, Raymond F, Corbeil J, Ouellette M,
Papadopoulou B. Whole-genome comparative
RNA expression profiling of axenic and
intracellular amastigote forms of Leishmania
infantum. Mol Biochem Parasitol 2009; 165: 32-
Ubeda JM, Legare D, Raymond F. Modulation of
gene expression in drug resistant Leishmania is
associated with gene amplification, gene deletion
and chromosome aneuploidy. Genome Biol 2008;
: R115.
Ribeiro JM, Vachereau A, Modi GB, Tesh RB. A
novel vasodilatory peptide from the salivary glands
of the sand fly Lutzomyia longipalpis. Science
; 243: 212-214.
Soares MB, Titus RG, Shoemaker CB, David JR,
Bozza M. The vasoactive peptide maxadilan from
sand fly saliva inhibits TNF-alpha and induces IL-
by mouse macrophages through interaction with
the pituitary adenylate cyclase-activating
polypeptide (PACAP) receptor. J Immunol 1998;
: 1811-1816.
Valenzuela JG, Belkaid Y, Rowton E, Ribeiro JM.
The salivary apyrase of the blood-sucking sand fly
Phlebotomus papatasi belongs to the novel Cimex
family of apyrases. J Exp Biol 2001; 204: 229-237.
Charest H, Matlashewski G. Developmental gene
expression in Leishmania donovani: differential
cloning and analysis of an amastigote-stagespecific gene. Mol Cell Biol 1994; 14: 2975-2984.
Boucher N, Wu Y, Dumas C. A common
mechanism of stage-regulated gene expression in
Leishmania mediated by a conserved 3'-
untranslated region element. J Biol Chem , et al.
; 277: 19511-1920.
MacFarlane J, Blaxter ML, Bishop RP, Miles MA,
Kelly JM. Identification and characterisation of a
Leishmania donovani antigen belonging to the 70-
kDa heat-shock protein family. Eur J Biochem
; 190: 377-384.
Van der Ploeg LH, Giannini SH, Cantor CR. Heat
shock genes: regulatory role for differentiation in
parasitic protozoa. Science 1985; 228: 1443-1446.
Joshi M, Dwyer DM, Nakhasi HL. Cloning and
characterization of differentially expressed genes
from in vitro-grown 'amastigotes' of Leishmania
donovani. Mol Biochem Parasitol 1993; 58: 345-
Margalit O, Somech R, Amariglio N, Rechavi G.
Microarray-based gene expression profiling of
hematologic malignancies: basic concepts and
clinical applications. Blood Rev 2005; 19: 223-
Singh N, Almeida R, Kothari H. Differential gene
expression analysis in antimony-unresponsive
Indian kala azar (visceral leishmaniasis) clinical
isolates by DNA microarray. Parasitology 2007;
: 777-7787.
Akopyants NS, Matlib RS, Bukanova EN.
Expression profiling using random genomic DNA
microarrays identifies differentially expressed
genes associated with three major developmental
stages of the protozoan parasite Leishmania major.
Mol Biochem Parasitol 2004; 136: 71-86.
Leifso K, Cohen-Freue G, Dogra N, Murray A,
McMaster WR. Genomic and proteomic
expression analysis of Leishmania promastigote
and amastigote life stages: the Leishmania genome
is constitutively expressed. Mol Biochem Parasitol
; 152: 35-46.
Waters NC, Geyer JA. Cyclin-dependent protein
kinases as therapeutic drug targets for antimalarial
drug development. Expert Opin Ther Targets
;7:7-17.
Krishna S, Eckstein-Ludwig U, Joet T. Transport
processes in Plasmodium falciparum-infected
erythrocytes: potential as new drug targets. Int J
Parasitol 2002; 32: 1567-1573.
Santos AL, d'Avila-Levy CM, Elias CG, Vermelho
AB, Branquinha MH. Phytomonas serpens:
immunological similarities with the human
trypanosomatid pathogens. Microbes Infect 2007;
: 915-921.
Perez-Victoria JM, Di Pietro A, Barron D, Ravelo
AG, Castanys S, Gamarro F. Multidrug resistance
phenotype mediated by the P-glycoprotein-like
transporter in Leishmania: a search for reversal
agents. Curr Drug Targets 2002; 3: 311-333.
Maiti AK, Ghosh K, Chatterjee U, Chakrobarti S,
Chatterjee S, Basu S. Epidermal growth factor
receptor and proliferating cell nuclear antigen in
astrocytomas. Neurol India 2008; 56: 456-462.
Werner C, Stubbs MT, Krauth-Siegel RL, Klebe
G. The crystal structure of Plasmodium falciparum
glutamate dehydrogenase, a putative target for
novel antimalarial drugs. J Mol Biol 2005; 349:
-607.
Burnie J, Carter T, Rigg G, Hodgetts S, Donohoe
M, Matthews R. Identification of ABC transporters
in vancomycin-resistant Enterococcus faecium as
potential targets for antibody therapy. FEMS
Immunol Med Microbiol 2002; 33: 179-189.
Asensio C, Levoin N, Guillaume C. Irreversible
inhibition of glucose-6-phosphate dehydrogenase
by the coenzyme A conjugate of ketoprofen: a key
to oxidative stress induced by non-steroidal antiinflammatory drugs? Biochem Pharmacol 2007;
: 405-416.
Gupta SK, Sisodia BS, Sinha S. Proteomic
approach for identification and characterization of
novel immunostimulatory proteins from soluble
antigens of Leishmania donovani promastigotes.
Proteomics 2007; 7: 816-823.
Walker J, Acestor N, Gongora R. Comparative
protein profiling identifies elongation factor-1beta
and tryparedoxin peroxidase as factors associated
with metastasis in Leishmania guyanensis. Mol
Biochem Parasitol 2006; 145: 254-264.
Jaffe CL, Rachamim N, Sarfstein R.
Characterization of two proteins from Leishmania
donovani and their use for vaccination against
visceral leishmaniasis. J Immunol 1990; 144: 699-
Gonzalez-Aseguinolaza G, Taladriz S, Marquet A,
Larraga V. Molecular cloning, cell localization and
binding affinity to DNA replication proteins of the
p36/LACK protective antigen from Leishmania
infantum. Eur J Biochem 1999; 259: 909-916.
Boceta C, Alonso C, Jimenez-Ruiz A. Leucine rich
repeats are the main epitopes in Leishmania
infantum PSA during canine and human visceral
leishmaniasis. Parasite Immunol 2000; 22: 55-62.
Handman E, Symons FM, Baldwin TM, Curtis JM,
Scheerlinck JP. Protective vaccination with
promastigote surface antigen 2 from Leishmania
major is mediated by a TH1 type of immune
response. Infect Immun 1995; 63: 4261-4267.
Samant M, Gupta R, Kumari S. Immunization with
the DNA-encoding N-terminal domain of
proteophosphoglycan of Leishmania donovani
generates Th1-Type immunoprotective response
against experimental visceral leishmaniasis. J
Immunol 2009; 183: 470-479.
Stober CB, Lange UG, Roberts MTM. From
genome to vaccines for leishmaniasis: Screening
novel vaccine candidates against murine
Leishmania major infection. Vaccine 2006; 24:
-2616.
Probst P, Stromberg E, Ghalib HW. Identification
and characterization of T cell-stimulating antigens
from Leishmania by CD4 T cell expression
cloning. J Immunol 2001; 166: 498-505.
Li YY, Jones SJ, Cherkasov A. Selective targeting
of indel-inferred differences in spatial structures of
homologous proteins. J Bioinform Comput Biol
; 4: 403-414.
Molano I, Alonso MG, Miron C. A Leishmania
infantum multi-component antigenic protein mixed
with live BCG confers protection to dogs
experimentally infected with L. infantum. Vet
Immunol Immunopathol 2003; 92: 1-13.
Carrion J, Folgueira C, Alonso C. Immunization
strategies against visceral leishmaniosis with the
nucleosomal histones of Leishmania infantum
encoded in DNA vaccine or pulsed in dendritic
cells. Vaccine 2008; 26: 2537-2544.
Wang CC, Bozdech Z, Liu CL. Biochemical
analysis of the 20 S proteasome of Trypanosoma
brucei. J Biol Chem 2003; 278: 15800-15808.
Isaza CE, Zhong X, Rosas LE. A proposed role
for Leishmania major carboxypeptidase in peptide
catabolism. Biochem Biophys Res Commun 2008;
: 25-29.
Lavazec C, Boudin C, Lacroix R.
Carboxypeptidases B of Anopheles gambiae as
targets for a Plasmodium falciparum transmissionblocking vaccine. Infect Immun 2007; 75: 1635-
Li X, Quigg RJ, Zhou J, Gu W, Nagesh Rao P,
Reed EF. Clinical utility of microarrays: current
status, existing challenges and future outlook. Curr
Genomics 2008; 9: 466-474.
Jayapal M, Melendez AJ. DNA microarray
technology for target identification and validation.
Clin Exp Pharmacol Physiol 2006; 33: 496-503.
Stears RL, Martinsky T, Schena M. Trends in
microarray analysis. Nat Med 2003; 9: 140-145.
Anderson JM, Oliveira F, Kamhawi S.
Comparative salivary gland transcriptomics of
sandfly vectors of visceral leishmaniasis. BMC
Genomics 2006; 7: 52.
Gurunathan S, Sacks DL, Brown DR. Vaccination
with DNA encoding the immunodominant LACK
parasite antigen confers protective immunity to
mice infected with Leishmania major. J Exp Med
; 186: 1137-1147.
Wei S, Marches F, Daniel B, Sonda S, Heidenreich
K, Curiel T. Pyridinylimidazole p38 mitogenactivated protein kinase inhibitors block
intracellular Toxoplasma gondii replication. Int J
Parasitol 2002; 32: 969-977.
